VFA
GNCA

Valeo Financial Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Valeo Financial Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-750
Closed -$2K – 2112
2021
Q1 		$2K Buy
+750
New +$2.22K ﹤0.01% 1857

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Valeo Financial Advisors's GNCA Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2021, closing a stake of 750 shares — an estimated $2K sold.

Valeo Financial Advisors first reported a position in GNCA in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 46 funds tracked by Wall St. Rank hold GNCA as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 750 Genocea Biosciences, Inc. shares in Q2 2021, an estimated $2K.
  • Valeo Financial Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's Genocea Biosciences, Inc. position peaked at $2K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.